BeiGene is planning to break ground in 2022 on a pharmaceutical manufacturing and research center in Hopewell, N.J. Located on the Princeton West Innovation Campus, the integrated complex will provide 400,000 sf of dedicated space for commercial-stage production of innovative cancer therapies. Offering up to 16,000 liters of biologics capacity, the facility will also include clinical R&D labs and collaborative office environments. IPS is the architect and engineer for the project, which will be built by DPR Construction. Completion is expected in late 2023 or early 2024.
BeiGene intends to invest several hundred million dollars in the complex, which is sited on a portion of the former Bristol-Myers Squibb campus. The 42-acre property was acquired from Lincoln Equities Group and offers over a million sf of developable real estate to accommodate future expansion.
| Organization | Project Role |
|---|---|
|
Integrated Project Services
|
Architect and Engineer
|
|
DPR Construction, Inc.
|
General Contractor
|
